|
Post by rockstarrick on Jun 26, 2018 5:36:37 GMT -5
I don't think so. The deterrent is the SLOW SALES for the past 3 years but don't get me wrong that's cool. It gives MNKD more runway before the BP's come sniffing around. BP is not convinced Technosphere is a viable alternative and at this point definitely not worth spending BILLIONS. MNKD will have to show quarterly sequential improvement in revenues for at least 6 Qtrs and don't forget MNKD went through 2 CRLs so that's in the back of BP's head also. MNKD has a decent runway to get Afrezza rolling. I would like to say the MANN Group could NIX any deal but they own very little at this point. I'm hoping for a $5 - $10B BUYOUT. If MNKD can sign a partner for TrepT and bring on a partner for EPI...that could be enough of a deterrent to prevent a BP from buying them. If you throw in an Int'l Partner also. Also I don't think anything will happen until the PEDS Trial is complete and they get approval. MNKD's US GROWTH Segment is the children. Mike has made that comment several times. So we have some time to see the progress of MNKD. The deterrent is not SLOW Sales. The deterrent has been providing the scientific data to support the clinical results and having the guy who can explain the data with credibility to the industry.
The path forward is well defined. First Dr. Kendall needs to get the ADA to make afrezza the standard of care for MDI. He should be able to do this in 6 months. Next, Dr. Kendall needs to get the ADA to make afrezza Step 2 for T2s.
If BP believes as I do these are two very possible and doable goals, past sales means nothing. In fact just the reality that MNKD is still around speaks volumes about the clinical results and cult following MNKD has had. MNKD for the last four years has basically been in a phase 4 study and every BP has just wanted them to go away. MNKD has been the cockroach of the pharma industry. No matter what was tried they keep coming back.
What have we learned in four years? First is lung function and PWDs are not only not losing function some have better results than when they started afrezza. At the three year mark as a diabetic they should all be seeing some decrease even if not using afrezza.
Second, some afrezza users started in 2008 on compassionate use. As far as I am aware non are reporting any lung function issues.
Third, clinical results in most cases have exceed most expectations.
Fourth, scientific studies are now verifying and supporting why afrezza is getting the clinical results it has. Additionally the STAT study non-compliant group mirrors the 171 results.
Fifth and most important IMO, ALL the FUD thrown at afrezza for years including "exploding lungs" has turned out to be unfounded FUD.
Ollie Brandicourt said afrezza would not be a viable product until 2020. I have to admit, he was right. So, at least one BP saw afrezza as a viable product four years ago. At this point afrezza is living rent free in the heads of every BP CEO in the diabetes space and every CEO in the Tech space who thinks they are getting into Cloud Monitoring and teledoc services. Any company like Buffets new JPM deal who wants to reduce insurance costs needs afrezza. Nothing can reduce micro and macro degeneration and heart disease like stopping the post meal spike and NOTHING but afrezza can stop the post meal spike and get the PWD back to baseline like a healthy pancreas or afrezza.
You want to stop T2 progression? Get the afrezza. Whats that worth? I would say at least $6B annually once named Step 2 and you are willing to take $5? I have faith Dr. Kendall will make afrezza the SOC. afrezza is the greatest advance in diabetes care since Banting and Best.
The next couple years will be interesting years for mnkd long Investors !! patient little suckers 😜
|
|
|
Post by golfeveryday on Jun 26, 2018 5:57:37 GMT -5
I don't think so. The deterrent is the SLOW SALES for the past 3 years but don't get me wrong that's cool. It gives MNKD more runway before the BP's come sniffing around. BP is not convinced Technosphere is a viable alternative and at this point definitely not worth spending BILLIONS. MNKD will have to show quarterly sequential improvement in revenues for at least 6 Qtrs and don't forget MNKD went through 2 CRLs so that's in the back of BP's head also. MNKD has a decent runway to get Afrezza rolling. I would like to say the MANN Group could NIX any deal but they own very little at this point. I'm hoping for a $5 - $10B BUYOUT. If MNKD can sign a partner for TrepT and bring on a partner for EPI...that could be enough of a deterrent to prevent a BP from buying them. If you throw in an Int'l Partner also. Also I don't think anything will happen until the PEDS Trial is complete and they get approval. MNKD's US GROWTH Segment is the children. Mike has made that comment several times. So we have some time to see the progress of MNKD. The deterrent is not SLOW Sales. The deterrent has been providing the scientific data to support the clinical results and having the guy who can explain the data with credibility to the industry.
The path forward is well defined. First Dr. Kendall needs to get the ADA to make afrezza the standard of care for MDI. He should be able to do this in 6 months. Next, Dr. Kendall needs to get the ADA to make afrezza Step 2 for T2s.
If BP believes as I do these are two very possible and doable goals, past sales means nothing. In fact just the reality that MNKD is still around speaks volumes about the clinical results and cult following MNKD has had. MNKD for the last four years has basically been in a phase 4 study and every BP has just wanted them to go away. MNKD has been the cockroach of the pharma industry. No matter what was tried they keep coming back.
What have we learned in four years? First is lung function and PWDs are not only not losing function some have better results than when they started afrezza. At the three year mark as a diabetic they should all be seeing some decrease even if not using afrezza.
Second, some afrezza users started in 2008 on compassionate use. As far as I am aware non are reporting any lung function issues.
Third, clinical results in most cases have exceed most expectations.
Fourth, scientific studies are now verifying and supporting why afrezza is getting the clinical results it has. Additionally the STAT study non-compliant group mirrors the 171 results.
Fifth and most important IMO, ALL the FUD thrown at afrezza for years including "exploding lungs" has turned out to be unfounded FUD.
Ollie Brandicourt said afrezza would not be a viable product until 2020. I have to admit, he was right. So, at least one BP saw afrezza as a viable product four years ago. At this point afrezza is living rent free in the heads of every BP CEO in the diabetes space and every CEO in the Tech space who thinks they are getting into Cloud Monitoring and teledoc services. Any company like Buffets new JPM deal who wants to reduce insurance costs needs afrezza. Nothing can reduce micro and macro degeneration and heart disease like stopping the post meal spike and NOTHING but afrezza can stop the post meal spike and get the PWD back to baseline like a healthy pancreas or afrezza.
You want to stop T2 progression? Get the afrezza. Whats that worth? I would say at least $6B annually once named Step 2 and you are willing to take $5? I have faith Dr. Kendall will make afrezza the SOC. afrezza is the greatest advance in diabetes care since Banting and Best.
my son was diagnosed with T1 recently. We went to an Afrezza friendly doc locally after not being able to get it at his clinic. She threw me a curve ball when she said she has only used it in T2’s but was willing to try it for him. With the head to head STAT study, I’m not sure if the ADA can ignore T2 for 18 months. The data is right there in front of their eyes as well as 4 years post launch use.
|
|
|
Post by rockstarrick on Jun 26, 2018 8:42:16 GMT -5
|
|
|
Post by rockstarrick on Jun 26, 2018 8:43:09 GMT -5
MannKind gained 'new credibility' for Afrezza at ADA, says H.C. Wainwright H.C. Wainwright analyst Oren Livnat said MannKind materially increased Afrezza's relevance and gained "new credibility" with multiple data presentations, including a well-attended symposium and oral presentation, at the American Diabetes Association meeting that was just held. He called the event an "eye-opening experience" that showed Afrezza's defining differentiation is not that it is inhalable, but that it "really is the best meal-time insulin, full stop." Following the ADA event, Livnat reiterated his Buy rating and $5 target on MannKind shares
|
|
|
Post by sportsrancho on Jun 26, 2018 9:00:20 GMT -5
OK here we go I was wrong, it’s Wainwright. To bad:-( Hold on for the ride!
|
|
|
ADA
Jun 26, 2018 9:04:46 GMT -5
via mobile
Post by uvula on Jun 26, 2018 9:04:46 GMT -5
Are people going to fall for this again? Look at the 1 year chart. Our last trip to $5 is very easy to see.
|
|
|
Post by sportsrancho on Jun 26, 2018 9:16:14 GMT -5
Are people going to fall for this again? Look at the 1 year chart. Our last trip to $5 is very easy to see. Its not our last trip to $5...it’s that Wainwright in Monte Carlo produced nothing much.
|
|
|
Post by awesomo on Jun 26, 2018 9:41:11 GMT -5
Welp, we are now below where we were when ADA started. That was fun...
|
|
|
Post by mango on Jun 26, 2018 11:12:44 GMT -5
|
|
|
Post by xanet on Jun 26, 2018 11:52:09 GMT -5
OK here we go I was wrong, it’s Wainwright. To bad:-( Hold on for the ride! Idk... it says the analyst reiterated the same Buy rating and $5 price target, after talking about how much new value there is for the company after the ADA. If so much value was added, the price target should have moved. This sounds more like jockeying for position, trying to get a piece of the pie. (How's that for a mixed metaphor?)
|
|
|
ADA
Jun 26, 2018 12:56:45 GMT -5
Post by mannmade on Jun 26, 2018 12:56:45 GMT -5
The price target did move as I recall didn't Wainwirght lower the target to $2 very recently?
|
|
|
ADA
Jun 26, 2018 13:14:19 GMT -5
Post by mnkdfann on Jun 26, 2018 13:14:19 GMT -5
The price target did move as I recall didn't Wainwirght lower the target to $2 very recently? There WAS a $2 mentioned, whether or not that was a typo was unclear at the time. Many people here argued that it was.
|
|
|
Post by awesomo on Jun 26, 2018 13:17:48 GMT -5
The price target did move as I recall didn't Wainwirght lower the target to $2 very recently? Seemed more like a typo considering the analyst kept saying "reiterated price target". Also note, this guy has a terrible track record and is part of the firm that raised money for the offering. So yeah, I'm not that excited by this. www.tipranks.com/analysts/oren-livnat
|
|
|
Post by compound26 on Jun 26, 2018 13:19:44 GMT -5
The price target did move as I recall didn't Wainwirght lower the target to $2 very recently? I think that $2 target was indeed a typo. Note in today's report, it is once again, " reiterate". All the recent reports from Wainwright has been "reiterate". It does not look like there was a downgrade recently. If there was a downgrade recently, then in today's report, it would be noted that it is an upgrade.
|
|
|
ADA
Jun 26, 2018 13:43:26 GMT -5
Post by mannmade on Jun 26, 2018 13:43:26 GMT -5
Was being sacastic... as we are currently at $2.
|
|